← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	802	+802	–	$30.2B
2	2 Danaher DHR $158B	779	+779	–	$34.4B
3	3 Novartis NVS $279B	763	+763	–	$17B
4	4 Agilent Technologies A $49.1B	518	+518	–	$11.9B
5	5 Regeneron Pharmaceuticals REGN $80.1B	371	+371	–	$17B
6	6 Illumina ILMN $41B	333	+333	–	$10.6B
7	7 Revvity RVTY $17B	284	+284	–	$3.28B
8	8 Myriad Genetics MYGN $397M	261	+261	–	$2.18B
9	9 Charles River Laboratories CRL $14.4B	225	+225	–	$1.93B
10	10 Ionis Pharmaceuticals IONS $7.1B	173	+173	–	$2.84B
11	11 Bruker BRKR $8.47B	165	+165	–	$1.76B
12	12 Alnylam Pharmaceuticals ALNY $30B	139	+139	–	$1.5B
13	13 Azenta AZTA $1.63B	131	+131	–	$571M
14	14 Sarepta Therapeutics SRPT $1.78B	128	+128	–	$904M
15	15 DELISTED SANGAMO THERAPEUTICS INC SGMO	99	+99	–	$240M
16	16 Standard BioTools LAB $248M	80	+80	–	$389M
17	17 Pacific Biosciences PACB $619M	71	+71	–	$74.4M
18	18 Fortress Biotech FBIO $63.4M	68	+68	–	$141M
19	19 Lineage Cell Therapeutics LCTX $232M	58	+58	–	$65.6M
20	20 Invesco Biotechnology & Genome ETF PBE $421M	40	+40	–	$41.7M
21	21 Imunon IMNN $5.84M	36	+36	–	$7.51M
22	22 Vericel Corp VCEL $2.06B	34	+34	–	$1.96M
23	ATHX 23 DELISTED Athersys, Inc. Common Stock ATHX	32	+32	–	$19M
24	24 Opus Genetics IRD $341M	20	+20	–	$804K
25	25 Arrowhead Research ARWR $8.25B	18	+18	–	$24.6M